Track the Scribe Therapeutics, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €460.2m. The latest transaction was disclosed on 29 July 2026 (Acquisition). Among the most active insiders: AH Bio Fund II, L.P.. Every trade is accessible without an account.
14
Insider Decl.
n/a
Thresholds
€63m
9 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Scribe Therapeutics, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$56.00.
41Σ signal
Buys €63mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
3,000 shares@ US$15.00100.0% of flowCommon StockSEC:0001781292-26-000007:0
Canonical exit: 21 Oct 2026 (T+90)
14 of 14 declarations
About Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. is a biotechnology company focused on developing gene therapies. It utilizes advanced technologies to design innovative treatments for genetic diseases.